HIV 1 VPR INDUCES G2 CELL CYCLE ARREST AND APOPTOSIS
HIV 1 VPR INDUCES G2 CELL CYCLE ARREST AND APOPTOSIS
批准号:
2895487
负责人:
IRVIN S.Y. CHEN
金额:
$25.33万
依托单位国家:
美国
项目类别:
财政年份:
1995
资助国家:
美国
项目状态:
已结题
起止时间:
1995-07-18 至 2003-04-30
关键词:
HeLa cells apoptosis cell cycle cysteine endopeptidases enzyme inhibitors flow cytometry gene mutation human immunodeficiency virus 1 human immunodeficiency virus 2 molecular pathology protein structure function simian immunodeficiency virus site directed mutagenesis tissue /cell culture virus infection mechanism virus protein
中文摘要
HIV-1基因产物是一种96个氨基酸的蛋白质,这一点很重要
对于病毒复制,可能是HIV-1致病的关键。
VPR在细胞感染后表达,也被发现包装在
在病毒粒子中。1995年,少年派是最早描述一部小说的人之一
HIV-1感染细胞表达VPR蛋白的表型
VPR在细胞周期的G2期发生停滞。他们随后
已发表的研究表明,VPR引起的细胞周期停滞之后是细胞凋亡
被逮捕的细胞。最近,他们发现,不仅从头开始
VPR的表达诱导细胞周期停滞,但VPR包装在
病毒粒子被引入细胞后,能够诱导细胞周期停滞
感染后的细胞。VPR已被证明可以增强病毒
VPR的一个潜在功能是阻止T细胞克隆
对抗原的反应扩张,从而抑制了早期的
建立有效的免疫反应。因此,VPR可能是一种
HIV-1疾病致病特征的关键决定因素和
进一步了解VPR的作用机制可能有助于
针对vpr的治疗药物的开发。
辐射或化学修饰对细胞DNA的损伤可导致
在细胞周期中的多个点发生停滞,包括所谓的G2
检查站。如果不能修复损伤,可能会导致细胞凋亡。
根据PI的说法,VPR是已知的唯一能引起这种情况的基因产物
哺乳动物细胞在G2期的有效细胞周期停滞。因此,一个
了解vpr的作用机制也很重要。
在理解导致停滞的信号转导通路方面
在哺乳动物细胞的G2检查点。以前,PI生成
开发了大量关于VPR行动的初步数据
开发了多种评估VPR功能的独特方法
这些试剂将使他能够有效地进一步发展
VPR作用机理的研究。具体目标是:目标1。
进一步鉴定HIV-1VPR引起的细胞周期停滞。目标2.目标
VPR介导的细胞凋亡的进一步表征目的3.鉴定细胞
参与VPR介导的细胞周期停滞和凋亡的因素。
英文摘要
The HIV-1 gene product is a 96 amino acid protein, which is important
for viral replication and likely to be critical for HIV-1 pathogenesis.
Vpr is expressed following infection of cells and is also found packaged
in virions. In 1995, the PI was among the first to describe a novel
phenotype of the Vpr protein whereby cells infected by HIV-1 expressing
Vpr undergo arrest at the G2 phase of the cell cycle. They subsequently
published that cell cycle arrest induced by Vpr is followed by apoptosis
of the arrested cells. Recently, they found that not only does de novo
expression of Vpr induce cell cycle arrest, but Vpr packaged into
virions is capable of inducing cell cycle arrest when introduced into
cells following infection. Vpr has been shown to augment virus
production and one potential function of Vpr is to prevent T-cell clonal
expansion in response to antigens thus suppressing an early step in
establishing an effective immune response. Therefore, Vpr may be a
critical determinant for pathogenic features of HIV-1 disease and
further understanding of Vpr mechanisms of action may facilitate the
development of therapeutic agents directed against Vpr.
Damage to cell DNA by irradiation or chemical modification can lead to
arrest at multiple points in the cell cycle including the so-called G2
checkpoint. Failure to repair the damage can lead to apoptosis.
According to the PI, Vpr is the only gene product known to induce such
an efficient cell cycle arrest in mammalian cells at G2. Thus, an
understanding of the mechanism of action of Vpr will also be important
in understanding the signal transduction pathways which lead to arrest
at the G2 checkpoint in mammalian cells. Previously, the PI generated
a considerable amount of preliminary data about Vpr action, developed
a number of unique assays for assessment of Vpr function and developed
reagents which will allow him to effectively carry forward further
studies on the mechanism of Vpr action. The specific aims are: Aim 1.
To further characterize cell cycle arrest by HIV-1 Vpr. Aim 2. To
further characterize Vpr mediated apoptosis Aim 3. To identify cellular
factors involved in Vpr-mediated cell cycle arrest and apoptosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative Core
-
批准号:10160815
-
项目类别:
-
资助金额:$19.44万
-
财政年份:2020
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Administrative Core
-
批准号:10614634
-
项目类别:
-
资助金额:$18.74万
-
财政年份:2020
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV
-
批准号:10468647
-
项目类别:
-
资助金额:$284.77万
-
财政年份:2020
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV
-
批准号:10614633
-
项目类别:
-
资助金额:$284.81万
-
财政年份:2020
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV
-
批准号:10160814
-
项目类别:
-
资助金额:$284.79万
-
财政年份:2020
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV
-
批准号:9890819
-
项目类别:
-
资助金额:$287.22万
-
财政年份:2020
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Administrative Core
-
批准号:10468648
-
项目类别:
-
资助金额:$20.05万
-
财政年份:2020
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
In Vivo Gene Editing for HIV-1 Cure
-
批准号:10549758
-
项目类别:
-
资助金额:$67.8万
-
财政年份:2019
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
In Vivo Gene Editing for HIV-1 Cure
-
批准号:10331787
-
项目类别:
-
资助金额:$67.8万
-
财政年份:2019
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
In Vivo Gene Editing for HIV-1 Cure
-
批准号:9753575
-
项目类别:
-
资助金额:$67.8万
-
财政年份:2019
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Anti-HIV Gene Therapy: Defend and Attack
-
批准号:8899031
-
项目类别:
-
资助金额:$225.61万
-
财政年份:2015
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Anti-HIV Gene Therapy: Defend and Attack
-
批准号:9468343
-
项目类别:
-
资助金额:$195.65万
-
财政年份:2015
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Anti-HIV Gene Therapy: Defend and Attack
-
批准号:9249485
-
项目类别:
-
资助金额:$213.55万
-
财政年份:2015
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Survival of the fittest HSPC repopulating clones by anti-HIV-1 gene-modification
-
批准号:9264595
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2014
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Mouse and mathematical models for HIV-1 suppression through HSPC
-
批准号:8915902
-
项目类别:
-
资助金额:$38.1万
-
财政年份:2014
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Survival of the fittest HSPC repopulating clones by anti-HIV-1 gene-modification
-
批准号:9058597
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2014
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Survival of the fittest HSPC repopulating clones by anti-HIV-1 gene-modification
-
批准号:8906934
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2014
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Gene engineering using CRISPR/Cas9 mutagenesis to eliminate latent HIV-1
-
批准号:8789998
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2014
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Survival of the fittest HSPC repopulating clones by anti-HIV-1 gene-modification
-
批准号:8790285
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2014
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
Hematopoietic stem/progenitor cell reservoirs
-
批准号:8659761
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2013
-
负责人:IRVIN S.Y. CHEN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: